Order byBest matchMost fresh

Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

Digest more
FDA gives Covid vaccine manufacturers instructions for next fall’s shot
The Food and Drug Administration gave Covid vaccine manufacturers instructions on what next fall’s Covid vaccines should target on Thursday, signaling it would prefer that they update the strain in t...

Continue reading

Novavax Stock Soars on FDA Approval for New COVID-19 Vaccine
Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli
The FDA plans to limit access to covid vaccines. Here’s why that’s not all bad.
Covid vaccines will soon be required to go through more rigorous trials to ensure that they really are beneficial for people who aren’t at high risk.

Continue reading

Here's what to know about the FDA's COVID-19 vaccine changes
FDA limits access to COVID-19 vaccine to older adults and other high-risk groups – a public health expert explains the new rules
FDA panel debates COVID vaccine recipe as questions swirl about fall shots
Government advisers are meeting Thursday to decide if COVID-19 vaccines need updating to improve protection this fall and winter — even as a new Trump administration policy has thrown into question wh...

Continue reading

US FDA Advisers to Weigh Composition of COVID Vaccines for 2025-2026
COVID shots should target newer strains of JN.1 variant in 2025-26 campaign, US FDA advisers say
FDA advisers recommend updating COVID shots to JN.1 strain
Moderna (MRNA), and Novavax (NVAX) agree as the FDA advisors recommend targeting JN.1 strain for updated COVID vaccines this fall. Read more here.
FDA sets new COVID booster guidelines for healthy adults under 65
The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.
RFK Jr. pledged not to upend US vaccine system, but big changes are underway
WASHINGTON — Robert F. Kennedy Jr. clinched the political support needed to become the nation’s top health official by pledging to work within the decades-old federal system for approval and use of vaccines. Yet his regulators are promising big changes that cloud the outlook for what shots might even be available.
Feedback